PMID- 32636949
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231111
IS  - 2221-285X (Electronic)
IS  - 1818-0876 (Print)
IS  - 1818-0876 (Linking)
VI  - 15
IP  - 3
DP  - 2020 May
TI  - Redox dual-stimuli responsive drug delivery systems for improving tumor-targeting 
      ability and reducing adverse side effects.
PG  - 311-325
LID - 10.1016/j.ajps.2019.06.003 [doi]
AB  - Cancer is a big challenge that has plagued the human beings for ages and one of 
      the most effective treatments is chemotherapy. However, the low tumor-targeting 
      ability limits the wide clinical application of chemotherapy. The 
      microenvironment plays a critical role in many aspects of tumor genesis. It 
      generates the tumor vasculature and it is highly implicated in the progression to 
      metastasis. To maintain a suitable environment for tumor progression, there are 
      special microenvironment in tumor cell, such as low pH, high level of glutathione 
      (GSH) and reactive oxygen species (ROS), and more special enzymes, which is 
      different to normal cell. Microenvironment-targeted therapy strategy could create 
      new opportunities for therapeutic targeting. Compared to other targeting 
      strategies, microenvironment-targeted therapy strategy will control the drug 
      release into tumor cells more accurately. Redox responsive drug delivery systems 
      (DDSs) are developed based on the high level of GSH in tumor cells. However, 
      there are also GSH in normal cell though its level is lower. In order to control 
      the release of drugs more accurately and reduce side effects, other drug release 
      stimuli have been introduced to redox responsive DDSs. Under the synergistic 
      reaction of two stimuli, redox dual-stimuli responsive DDSs will control the 
      release of drugs more accurately and quickly and even increase the accumulation. 
      This review summarizes strategies of redox dual-stimuli responsive DDSs such as 
      pH, light, enzyme, ROS, and magnetic guide to delivery chemotherapeutic agents 
      more accurately, aiming at providing new ideas for further promoting the drug 
      release, enhancing tumor-targeting and improving anticancer effects. To better 
      illustrate the redox dual-stimuli responsive DDS, preparations of carriers are 
      also briefly described in the review.
CI  - (c) 2019 Published by Elsevier B.V. on behalf of Shenyang Pharmaceutical 
      University.
FAU - Li, Ruirui
AU  - Li R
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
FAU - Peng, Feifei
AU  - Peng F
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
FAU - Cai, Jia
AU  - Cai J
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
FAU - Yang, Dandan
AU  - Yang D
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190821
PL  - Netherlands
TA  - Asian J Pharm Sci
JT  - Asian journal of pharmaceutical sciences
JID - 101535338
PMC - PMC7327776
OTO - NOTNLM
OT  - Chemotherapy
OT  - Drug delivery system
OT  - Dual-stimuli responsive
OT  - Redox responsive
OT  - Tumor-targeting
COIS- The authors report no conflicts of interest. The authors alone are responsible 
      for the content and writing of this article.
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
PMCR- 2019/08/21
CRDT- 2020/07/09 06:00
PHST- 2019/01/22 00:00 [received]
PHST- 2019/03/28 00:00 [revised]
PHST- 2019/06/20 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
PHST- 2019/08/21 00:00 [pmc-release]
AID - S1818-0876(19)30119-9 [pii]
AID - 10.1016/j.ajps.2019.06.003 [doi]
PST - ppublish
SO  - Asian J Pharm Sci. 2020 May;15(3):311-325. doi: 10.1016/j.ajps.2019.06.003. Epub 
      2019 Aug 21.